Alphabet's isomorphic labs pursuing substantial funding for AI drug discovery initiatives

Alphabet Inc.'s research division, Isomorphic Labs, is reportedly engaged in discussions to secure approximately $5 billion in fresh capital. This significant funding push is intended to bolster the lab's ongoing work applying artificial intelligence methodologies to the complex field of drug discovery. Information regarding these talks comes from individuals familiar with the ongoing negotiations. The substantial investment aims to accelerate Isomorphic Labs' advancements in leveraging AI to revolutionize pharmaceutical research and development.